Sysmex Suisse


When testing for bladder cancer – whether as screening or monitoring – there always seems to be an undesirable side to it:

  • The sensitive methods (cystoscopy) are invasive, making patient acceptance difficult.
  • The non-invasive cytology is characterised by high specificity, but low sensitivity, which is hardly acceptable when it comes to serious disease such as cancer.

Screening for bladder cancer among risk groups is important, and for programmes to be successful, patient compliance is necessary.

For those already diagnosed with bladder cancer, the high recurrence rate of up to 85% calls for frequent monitoring.

BTAstat offers a solution

BTAstat is a non-invasive rapid test performed from urine. It is more sensitive than urine cytology and suitable for screening purposes and monitoring support. 

  • Physicians benefit from the higher sensitivity, easy access, low effort and cost-efficiency of the method.
  • Bladder cancer patients will appreciate the convenient, non-invasive procedure from an ordinary urine sample – and experience a relief from their diagnostic burden since this test may allow reducing cystoscopies to the necessary minimum.

Sample material and test procedure

Requires only three drops of voided urine.
Please note: Samples showing macrohaematuria have to be excluded from the test, as they will not produce a valid result.
1)    Add three drops of urine using the included pipette.
2)    Read the result after five minutes of incubation.

Test principle and specifications

Immunochromatographic test on bladder tumour antigen hCFHrp (BTA) from urine

Sensitivity: 52.5 – 78.0 %


For risk groups such as

  • smokers
  • hair dressers, painters, road constructors, synthetics industry staff, etc. within the scope of occupational health (contact with chemicals contained in paints, tar, solvents)
  • patients with a record of schistosomiasis



Following an approach described in a Spanish study (reference below), the number of cystoscopies in monitoring bladder cancer can be reduced:

Patients suffering from a superficial tumour can be differentiated in patients with high-grade or low-grade tumours, dependent on their probability to recur. Only high-grade patients undergo cystoscopy, while low-grade patients have a BTAstat test performed and, only in case of a positive test, undergo additional cystoscopy.

Seven patients were missed (false-negative test), but all of them belonged to the low-grade group.

Following a monitoring workflow as described above, you can

  • reduce the total number of unnecessary cystoscopies
  • prolong the time interval until the next follow-up with cystoscopy



References / Literature

[1] Ecke:
[2] Raitanen:
[3] Garcia-Valendria:


Sysmex Suisse AG

Tödistrasse 50

CH-8810 Horgen

+41 44 718 38 38

+41 44 718 38 39

Sysmex Suisse AG

Rue Galilée 15

CH-1400 Yverdon-les-Bains

+41 24 423 93 93

+41 24 423 93 98

Explore more

Copyright © Sysmex Europe GmbH. All rights reserved.
Personnalisez vos paramètres

Nous utilisons des cookies pour vous permettre une utilisation optimale de notre site web et pour améliorer notre communication avec vous. Nous tenons compte de vos choix et nous n’utilisons que les données pour lesquelles vous nous donnez votre consentement.

* Peut conduire à des restrictions dans les contenus et l’expérience d’utilisateur
Détails sur les cookies
Cookies strictement nécessaires
Ces cookies contribuent à l’exploitation de notre site web en autorisant des fonctions de base, telles que la navigation sur le site et l’accès à des zones sécurisées de notre site web. Notre site web ne peut pas fonctionner correctement sans ces cookies.
Cookies de statistiques
Ces cookies nous aident à comprendre comment des visiteurs interagissent avec notre site web, en récoltant des informations de façon anonyme. Ces informations nous permettent d’améliorer constamment notre offre.
Cookies marketing
Ils sont utilisés pour tracer des visiteurs sur des sites web. Ils ont pour objet de montrer des annonces pertinentes et attractives à chaque utilisateur et donc précieuses pour les éditeurs et les annonceurs tiers.